|
|
|
8:00-9:00 |
Exhibits and Research Presentations-
Poster Viewing |
|
|
Hong Kong Hall 1
See Poster
Presentations (Over 150 research posters
presented)
|
|
9:00-9:15 |
ISPOR Service Awards Presentation |
|
|
Auditorium
(Chinese translation available)
Peter Neumann ScD President, and Associate Professor, Harvard School of
Public Health, Boston, MA, USA
|
|
9:15-10:30 |
Second Plenary Session |
|
|
DEVELOPMENT AND IMPLEMENTATION OF
PHARMACOECONOMICS REQUIREMENTS: INTERNATIONAL EXPERIENCES
Moderator:
Wen Chen PhD, Professor and Associate Dean, School of
Public Health, Fudan University, Shanghai, P.R. China
Biographical Info
EXPERIENCES OF PHARMACOECONOMICS OVERSEAS: DEVELOPMENTS IN
METHODS
Michael Drummond, PhD, Professor of
Health Economics, Centre for Health Economics, University
of York, Heslington, York, UK
Biographical Info
The growing use of economic evaluation in decisions about
the pricing and reimbursement of pharmaceuticals has led
to more scrutiny of methods. This presentation will
discuss some of the main issues that have arisen, such as
the selection of alternative therapies for comparison with
the drug of interest, the role of decision-analytic
modelling, the measurement and valuation of health
outcomes and the characterization of uncertainty.
EXPERIENCES IN PHARMACOECONOMICS OVERSEAS: POLICIES
AND PROCEDURES
Suzanne Hill PhD,
Scientist, Policy, Access and Rational Use, Medicines
Policy and Standards, World Health Organization, Geneva,
Switzerland.
Biographical Info
A number of countries have developed initiatives to use
pharmacoeconomics in decision-making, including health
tehnology assessment in Canada and Spain, reimbursement
decisions (Australia, The Netherlands and Canada) and
comprehensive health care guidance (the UK). In this
presentation, the experiences of implementing these
policies in two countries (Australia and the UK) and the
challenges of balancing considerations such as quality,
innovation, drug prices and value for money will be
discussed. |
|
|
|
|
10:30-10:45 |
Break, Exhibits and Research Presentations- Poster Viewing
Hong Kong Hall 1 |
|
|
See Poster
Presentations (Over 150 research posters
presented)
|
|
10:45-11:45 |
Podium Sessions II |
|
|
GI DISORDERS Shanghai Room 1
Moderator: Surachat Ngorsuraches PhD, RPh, Head of Pharmacy Administration Department, Prince of Songkla University, Hatyai, Songkhla, Thailand
GI2
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SACRAL
NERVE STIMULATION (SNS) WITH INTERSTIM ® IN FAECAL
INCONTINENCE (FI) PATIENTS IN SPAIN.
Rodriguez JM1, Navarro A2, Muñoz A2, Brosa M3,
Serrano-Contreras D4, Minda K5,
1Medtronic Iberica,
Madrid, Spain; 2 Hospital Mutua de Terrassa, Terrassa,
Barcelona, Spain; 3 Oblikue Consulting, Barcelona, Spain;
4 Medtronic Iberica, Madrid, Spain; 5 Medtronic S.A,
Tolochenaz, Morges, Switzerland
GI3
COMPARATIVE EFFECTIVENESS OF LAMIVUDINE MONOTHERAPY FOR
PATIENTS WITH CHRONIC HEPATITIS B
Sun X1, Zhou R2, Li P2, Li Y3, Guyatt G4, 1The Chinese
Cochrane Centre, West China Hospital, Sichuan University, Chengdu, China; 2 West China Hospital, Sichuan University,
Chengdu, Sichuan, China; 3 Chinese Evidence-Based Medicine
Center, West China Hospital, Chengdu, Sichuan, China; 4
Department of Clinical Epidemiology and Biostatistics,
McMaster University, Hamilton, Ontario, Canada
GI4
OUTCOMES AND COSTS OF GENERIC AND TRADE RANITIDINE USE IN
THE UNITED STATES AND JAPAN
Kamae I1,
Yanagisawa S1, Oderda GM2, Otsuka M3, Jorgenson
J4, Otsuka K1, Brixner D2, 1Kobe University, Kobe, Japan;
2 University of Utah College of Pharmacy, Salt Lake City,
UT, USA; 3 Musashino University, Nishi-Tokyo, Japan; 4
University of Utah Hospital and Clinics, Salt Lake City,
UT, USA
HEALTH CARE USE & POLICY STUDIES
II Auditorium (Chinese translation available)
Moderator: Eui-Kyung Lee PhD, Senior Research Fellow and Director, Korea Institute for Health and Social Affairs, Seoul, South Korea
HP5
CATASTROPHIC AND POVERTY IMPACTS OF OUT-OF-POCKET HEALTH
PAYMENTS BEFORE AND AFTER THE UNIVERSAL HEALTH CARE
COVERAGE IMPLEMENTATION IN THAILAND.
Limwattananon S1, Prakongsai P2, Tangcharoensathien V3,
1Khon Kaen University, Amphoe Muang, Khon Kaen, Thailand;
2 International Health Policy Program, Amphoe Muang,
Nonthaburi, Thailand; 3 International Health Policy
Program, Nonthaburi, Thailand
HP7
SURVEILLANCE OF ANTIMICROBIAL RESISTANCE AND USE IN THE
COMMUNITY: A TIME-SERIES STUDY.
Kulkarni RA1, Thatte UM2, Holloway KA 3, Sørensen TL4,
Koppikar GV1, Shinkre NN1, Chaudhury RR5, 1BYL Nair Ch
hospital, Mumbai, Maharashtra, India; 2 BYL Nair
Charitable hospital, Mumbai, Maharashtra, India; 3 World
Health Organisation, Geneva, Switzerland; 4 Bispebjerg
Hospital, Bispebjerg, The Netherlands; 5 Delhi Society for
Promotion of Rational Use of Drugs, Delhi, India
HP8
OPTIMAL CONTRACT DESIGN UNDER PRICE-VOLUME AGREEMENTS
Zhang H, Zaric GS, PhD, The University of Western Ontario,
London, ON, Canada
INFECTION
Shanghai Room 5
Moderator: Eric Qiong Wu PhD, Analysis Group Inc., Boston, MA, USA
IN1
ADVERSE EVENTS OF ANTIRETROVIRAL THERAPIES CONTAINING
NEVIRAPINE OR EFAVIRENZ BASED ON INTENSIVE ADR MONITORING
DATABASE
Kulsomboon V1, Maleewong U1, Suwankaesawong V2,
Jameekornkul C2, 1Chulalongkorn University, Bangkok,
Thailand; 2 Food and Drug Administration Office, Nonthaburee, Thailand
IN2
PRODUCTIVITY COSTS AND CARER BURDEN OF HOME PARENTERAL
ANTIBIOTIC THERAPY
Neilson GS, Neilson JS, Whitby M, Princess Alexandra
Hospital, Brisbane, Queensland, Australia
IN3
ECONOMIC EVALUATION OF VACCINATION AGAINST POLIOMYELITIS
IN MALAYSIA: ORAL POLIO VACCINE (OPV) VS INACTIVATED POLIO
VACCINE (IPV)
Aljunid SM, MD, Universiti Kebangsaan Malaysia, Cheras,
Kuala Lumpur, Malaysia
IN4
MODELING ECONOMIC BENEFITS OF SUPPRESSING VIRAL
REPLICATION IN CHRONIC HEPATITIS B (CHB) PATIENTS IN
CHINA: A COST-EFFECTIVENESS ANALYSIS OF ENTECAVIR AND
LAMIVUDINE BASED ON A PHASE III CLINICAL TRIAL
Yuan Y1, Iloeje U2, Li H3, Hay J4, Bi Yao GB5,
1Bristol-Myers Squibb Company, Plainsboro, NJ, USA; 2
Bristol-Myers Squibb Company, Wallingford, CT, USA; 3
Bristol-Myers Squibb Co, Wallingford, CT, USA; 4
University of Southern California, Los Angeles, CA, USA; 5
Jin An District Hospital & Shanghai Fudan University,
Shanghai, China
MENTAL HEALTH
Shanghai Room 6
Moderator: Lillian Yu-Jen Wang MS, Health Economics and Market Access Manager, Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan
MH2
THE IMPACT OF SCHIZOPHRENIA ON CAREGIVERS: BURDEN OF
ILLNESS AND QUALITY OF LIFE
Crowley S1, Adams J2, Nand V3, Le Reun C4, Mudge M2,
Eggleston A3, Schrover R5, Brown A2, 1University of
Melbourne, North Ryde, NSW, Australia; 2 Medical
Technology Assessment Group, Chatswood, NSW, Australia; 3
Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia; 4 M-TAG
Pty Ltd, Chatswood, Australia; 5 Janssen-Cilag Pty
Ltd/University of Melbourne, North Ryde, NSW, Australia
MH3
THE QUALITY OF LIFE IN DEPRESSED OUTPATIENTS: 6 MONTH
FOLLOW-UP STUDY IN SHANGHAI, CHINA
Ji J1, Chen X2, Tan-Mulligan A3, Sheng F3, 1Zhongshan
Hospital, Fudan University, Shanghai, China; 2 Fudan
University, Shanghai, China; 3 GlaxoSmithKline
Pharmaceuticals China, Shanghai, China
MH4
PHARMACOECONOMIC EVALUATION OF RELAPSED AND NON-RELAPSED
GENERALISED ANXIETY DISORDER PATIENTS
Jorgensen TR1, François C2, Despiegel N2, 1H. Lundbeck
A/S, Valby, Copenhagen, Denmark; 2 H. Lundbeck A/S, Paris,
France
URINARY/KIDNEY DISORDERS
Shanghai Room 2
Moderator: Nathorn Chaiyakunapruk PharmD, PhD, Assistnat Professor, Department of Pharmacy Practice, Naresuan University, Pitsanuloak, Thailand
UK1
A REGIONAL ASIAN ANALYSIS OF THE COST-EFFECTIVENESS OF
EARLY IRBESARTAN TREATMENT VERSUS CONVENTIONAL
ANTIHYPERTENSION TREATMENT, AND LATE IRBESARTAN TREATMENT
IN PATIENTS WITH TYPE 2 DIABETES HYPERTENSION AND KIDNEY
DISEASE
Annemans L1, Demarteau N2, Hu S3, Lee TJ4, Morad Z5,
Thanom S6, Yang WC7
1IMS Health and Ghent University, Brussels, Belgium, 2 IMS
Health, Brussels, Belgium, 3Fudan University (former
Shanghai Medical University), Shanghai, China, 4College of
Medicine, Hallym University, Chuncheon, South Korea,
5Hospital Kuala Lumpur, Kuala Lumpur, Malaysia,
6Phramongkutklao Army Hospital, Bangkok, Thailand,
7Veteran General Hospital and National Yang-Ming
University, School of Medicine, Taipei, Taiwan
UK2
ESTIMATED ANNUAL COST OF OVERACTIVE BLADDER IN THAILAND
Prasobsanti K1, Ponprasit K2, 1Chulalongkorn University
Hospital, Bangkok, Thailand; 2 Pfizer Thailand Ltd,
Bangkok, Thailand
UK3
ETHICAL DIMENSION OF RESOURCE ALLOCATION: THE CASE OF
SCALING UP ACCESS TO RENAL REPLACEMENT THERAPY IN THAILAND
Tangcharoensathien V1, Prakongsai P2, Kasemsup V3,
Teerawattananon Y4, 1International Health Policy Program, Nonthaburi, Thailand; 2 International Health Policy
Program, Amphoe Muang, Nonthaburi, Thailand; 3 Mahidol
University, Bangkok, Thailand; 4 International Health
Policy Program - Thailand, Nonthaburi, Thailand
UK4
ECONOMIC ANALYSIS OF ORAL CARBONACEOUS ADSORBENT AST-120
IN DELAYING THE INITIATION OF DIALYSIS TREATMENTS AMONG
PATIENTS WITH CHRONIC RENAL FAILURE
Kang HY1, Cho WH1, Lee SM2, Kim HJ3, Woo TW4, 1Yonsei
University, Seoul, South Korea; 2 Yonsei University,
Graduate School, Seoul, South Korea; 3 Pochon CHA
University, Pochon,
Kyoung-gi, South Korea; 4 CJ Corp, Seoul, South Korea
|
|
11:45-12:00 |
Break and Research Presentations- Poster Viewing Hong Kong Hall 1 |
|
|
See Poster
Presentations (Over 150 research posters
presented)
|
|
12:00-13:00 |
Workshop Session III
- see workshops details |
|
|
HEALTH POLICY
W11 ISSUES IN DRUG PRICING, REIMBURSEMENT, AND ACCESS IN
THE ASIA-PACIFIC REGION
Auditorium (Chinese translation available)
Discussion Leaders: Stuart O. Schweitzer PhD,
Professor of Health Services, UCLA School of Public Health,
Los Angeles, CA USA; , Professor Yingyao Chen PhD, Professor
of Hospital Management, Fudan University School of Public
Health, Shanghai, PR China
W12 INTERPRETING REAL WORLD PHARMACOECONOMIC
INTERVENTIONS – DIFFICULTIES ARISING FROM UNFORESEEN ACCESS
EFFECTS
Shanghai Room 2
Discussion Leader: Jeonghoon Ahn PhD, Assistant
Professor, University of Southern California, Los Angeles,
CA, USA
OUTCOMES RESEARCH METHODS
W14 PHARMACOECONOMICS: EVALUATING FREE SOFTWARE ON THE
INTERNET FOR COST EFFECTIVENESS ANALYSIS, DECISION ANALYSIS
AND NUMBER
NEEDED TO TREAT CALCULATIONS
Shanghai Room 6
Discussion Leader: William McGhan PharmD, PhD,
Professor of Pharmacy & Health Policy, University of the
Sciences, Philadelphia, PA, USA
W15 RETROSPECTIVE DATABASES IN THE UNITED STATES, EUROPE
AND ASIA
Shanghai Room 1
Discussion Leaders: Diana Brixner PhD, Associate
Professor, University of Utah College of Pharmacy, Salt
Lake City, UT, USA; Gary M Oderda PharmD, MPH,
Professor, University of Utah College of Pharmacy, Salt
Lake City, UT, USA
|
|
13:00-14:30 |
Lunch, Exhibits and Research
Presentations- Poster Viewing |
|
|
See Poster
Presentations
|
|
13:00-14:00 |
IMS
SYMPOSIUM (ALL ARE INVITED TO ATTEND)
Auditorium |
|
|
IMPLEMENTING PHARMACOECONOMIC GUIDELINES IN ASIA: WILL
INCREASING EFFICIENCY HELP CONTAIN COSTS?
Budget constraints and growing public demand for
innovative drugs have made the efficient delivery of
quality health care a major priority worldwide. As a
result, an increasing number of countries have implemented
pharmacoeconomic guidelines and requirements.
As Asian health care systems move into an era of budget
constraints and rising pharmaceutical costs, many policy
makers are looking towards pharmacoeconomic requirements
as a cost control solution. But is pharmacoeconomics an
effective cost containment strategy?
A panel of global experts will discuss this pressing
question. Key opinion leaders from Asia will discuss the
anticipated impact of pharmacoeconomic requirements on
pharmaceutical spending in the region. Experts from
Europe, Australia and Asia will explore the evolution of
pharmacoeconomic requirements and discuss their value in
containing pharmaceutical spending.
8More
about symposium
|
|
14:30-14:45 |
Break |
|
|
|
|
14:45-15:45 |
Workshop Session IV
- see workshops details |
|
|
HEALTH POLICY
W16 THE ECOMONIC BENEFITS OF WORKSITE PROMOTION & DISEASE
PREVENTION IN THE US: LESSONS FOR ASIA
Shanghai Room 6
Discussion Leaders: Louis Yen PhD, Assistant Research
Scientist, The University of Michigan, Ann Arbor, MI, USA;
Dee W Edington PhD, Director & Professor, The University
of Michigan, Ann Arbor, MI, USA
W17 HOW ARE PHARMACEUTICAL PRICES AND ACCESS SET IN
COUNTRIES IN THE ASIA-PACIFIC REGION: COMPARING “HEALTH
POLICY” AND “HEALTH INDUSTRY POLICY”
CANCELED
OUTCOMES RESEARCH METHODS
W19 CURRENT DEVELOPMENTS AND ISSUES ABOUT DRUG SAFETY
Auditorium (Chinese translation available)
Discussion Leaders: Jeff Jianfei Guo PhD, Assistant
Professor, University of Cincinnati, Cincinnati, OH, USA;
Yong Hua Jing MS, Research Assistant, University of
Cincinnati, Cincinnati, OH, USA; Wenmin Du PhD, Deputy
Director, Shanghai Adverse Drug Reaction Monitoring
Center, Shanghai, Shanghai, China
W20 EQ-5D AND OTHER GENERIC MEASURES OF HEALTH
Shanghai Room 1
Discussion Leaders:, Executive Director,
EuroQoL Group, Centre for Health Policy and Law,
Rotterdam, Netherlands; Paul Kind, Principal Investigator,
Outcomes Research Group, York, United Kingdom
|
|
15:45-16:00 |
Break and Research Presentations- Poster Viewing
Hong Kong Hall 1 |
|
|
See Poster
Presentations (Over 150 research posters
presented)
|
|
16:00-17:00 |
Co-Sponsor Special Sessions II
|
|
|
EVIDENCE-BASED MEDICINE IN CHINA
Auditorium (Chinese translation available)
Youping Li PhD, President, Chinese Cochrane Center
and Professor, West China Center of Medical Sciences,
Sichuan University, Sichuan, China
INTERNATIONAL COMPARISON OF THE
PHARMACEUTICAL EXPENDITURES AND PHARMACEUTICAL POLICY IN
JAPAN
Shanghai Room 5
Hiroyuki Sakamaki, MBA, Director and Chief Researcher, Research Department, Institute for Health Economics and Policy, Japan
FORMULARY ASSESSMENT AND DRUG
CONTROL IN MALAYSIA
Shanghai Room 6
Samsinah Hussain PhD, Associate Professor, Head of Department of Pharmacy, University of Malaysia, and Member of the Drug Control Authority (DCA) and
Pharmacy Board, Ministry of Health, Malaysia
SINGAPORE HEALTH AUTHORITY CENTER
FOR DRUG ADMINISTRATION FORUM
Shanghai Room 1
Moderator: Phua Kai Hong PhD, Joint Professor of Health Policy and Management, Lee Kuan Yew School of Public Policy and Yong Loo Lin School of Medicine,
National University of Singapore, Singapore
Shu-Chen Li PhD, MS, MBA, Visiting Specialist and Consultant, Center for Drug Administration, Health Science Authority, and Associate Professor, Department of
Pharmacy, National University of Singapore, Singapore;
Eileen Lim, Official, Center for Drug Administration, Health Science Authority, Singapore
ISPOR ASIA MEDICAL DEVICE &
DIAGNOSTICS COUNCIL FORUM
Shanghai Room 2
Welcome & Opening Remarks
Nancy S. Travis, Chair, ISPOR Asia Pacific Medical Device & Diagnostics Council Steering Committee, Associate Vice President (Asia), Advanced Medical
Technology Association (AdvaMed)
Marilyn Dix Smith PhD, ISPOR Founding Executive Director, ISPOR
ISPOR and the Medical Device
World - Synergies and Unique Issues
Michael Drummond PhD, Professor of Health
Economics, University of York, Centre for Health Economics
and ISPOR President-elect
Medical Device Outcomes Research
Issues
Isao Kamae MD, PhD, Professor of Biostatistics and
Health Decision Sciences, Graduate School of Medicine,
Kobe University, Kobe, Japan
Jie Chen PhD, Director, Key Lab of Health
Technology Assessment, Ministry of Health and Professor,
Fudan University, Shanghai, China
Ashoke Bhattacharjya PhD, Executive Director,
Health Policy and Economics, Johnson & Johnson,
Titusville, NJ, USA
|
|
17:00-17:15 |
Break |
|
|
|
|
17:15-17:30 |
ISPOR Research Awards Presentation
and Closing Remarks |
|
|
Auditorium (Chinese translation available) |
|
17:15-18:00 |
ISPOR
Asia-Pacific Medical Device & Diagnostics Council Forum
(by invitation only) |
|
|
Hong Kong Hall IV |
|
18:00-20:00 |
ISPOR Asia-Pacific Medical Device & Diagnostics Council
Reception & Dinner
(by invitation only) |
|
|
Hong Kong Hall IV |
|
